Latest Diagnostics News

Page 2 of 72
Radiopharm Theranostics has reached final alignment with the U.S. FDA on a single pivotal Phase 3 trial for RAD101, its brain metastases imaging agent. The approximately 280-patient study is expected to begin dosing in the first half of 2027, moving the program from regulatory planning towards execution.
Ada Torres
Ada Torres
4 Nov 2026
Revvity has lifted its full-year 2026 outlook after reporting stronger third-quarter revenue, organic growth and profitability. The life sciences and diagnostics group is also preparing to sell its China immunodiagnostics business for up to US$200 million.
Ada Torres
Ada Torres
4 Nov 2026
Waters delivered a stronger-than-expected third quarter, lifting every component of its 2026 guidance while organic growth accelerated across instruments, consumables and reagents. The company also acquired MOBILion Systems to extend its mass spectrometry technology into proteomics.
Sophie Babbage
Sophie Babbage
4 Nov 2026
IDEXX Laboratories has raised its 2026 revenue and earnings outlook after reporting 10% third-quarter revenue growth and an 18% rise in diluted EPS. The upgrade came alongside rapid adoption of its inVue Dx analyzers, although acquisition costs prompted a lower full-year operating margin forecast.
Ada Torres
Ada Torres
2 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026
INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
Ada Torres
2 Nov 2026
Alvo Minerals has expanded its Bluebush heavy rare earth project in Brazil, with new ground, encouraging clay intercepts and Florence drilling advancing toward a maiden resource. But quarter-end cash of A$227,000 covered only 0.28 quarters of reported outgoings before a subsequent A$1 million placement and option exercises.
Maxwell Dee
Maxwell Dee
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Axel REE has produced its first mixed rare earth carbonate from Woolrich column-leach solutions, while expanding the Caladão resource to 708.6 million tonnes. The results strengthen the proposed ISR pathway, but the decisive test remains field-scale recovery and process consistency.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026
Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive